Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 1/2019

01-02-2019

Contact Dermatitis to Medications and Skin Products

Authors: Henry L. Nguyen, James A. Yiannias

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2019

Login to get access

Abstract

Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), topical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non-formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimerosal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.
Literature
1.
Diepgen TL, Ofenloch RF, Bruze M, Bertuccio P, Cazzaniga S, Coenraads PJ, Elsner P, Goncalo M, Svensson Å, Naldi L (2016) Prevalence of contact allergy in the general population in different European regions. Br J Dermatol 174(2):319–329CrossRefPubMed
2.
Thyssen JP, Linneberg A, Menné T, Johansen JD (2007) The epidemiology of contact allergy in the general population—prevalence and main findings. Contact Dermatitis 57(5):287–299CrossRefPubMed
3.
Nielsen NH, Menne T (1992) Allergic contact sensitization in an unselected Danish population. The Glostrup Allergy Study, Denmark. Acta Derm Venereol 72(6):456–460PubMed
4.
Nielsen NH, Linneberg A, Menne T et al (2001) Allergic contact sensitization in an adult Danish population: two cross-sectional surveys eight years apart (the Copenhagen Allergy Study). Acta Derm Venereol 81(1):31–34CrossRefPubMed
5.
Thyssen JP, Linneberg A, Menne T, Nielsen NH, Johansen JD (2009) Contact allergy to allergens of the TRUE-test (panels 1 and 2) has decreased modestly in the general population. Br J Dermatol 161(5):1124–1129CrossRefPubMed
6.
Schafer T, Bohler E, Ruhdorfer S et al (2001) Epidemiology of contact allergy in adults. Allergy 56(12):1192–1196CrossRefPubMed
7.
Dotterud LK, Smith-Sivertsen T (2007) Allergic contact sensitization in the general adult population: a population-based study from Northern Norway. Contact Dermatitis 56(1):10–15CrossRefPubMed
8.
Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE (2002) Contact allergy and allergic contact dermatitis in adolescents: prevalence measures and associations. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS). Acta Derm Venereol 82(5):352–358CrossRefPubMed
9.
Nielsen NH, Linneberg A, Menne T et al (2002) Incidence of allergic contact sensitization in Danish adults between 1990 and 1998; the Copenhagen Allergy Study, Denmark. Br J Dermatol 147(3):487–492CrossRefPubMed
10.
Lim HW, Collins SAB, Resneck JS Jr, Bolognia JL, Hodge JA, Rohrer TA, van Beek MJ, Margolis DJ, Sober AJ, Weinstock MA, Nerenz DR, Smith Begolka W, Moyano JV (2017) The burden of skin disease in the United States. J Am Acad Dermatol 76(5):958–972 e952CrossRefPubMed
11.
Clark SC, Zirwas MJ (2009) Management of occupational dermatitis. Dermatol Clin 27(3):365–383 vii–viiiCrossRefPubMed
12.
Schwindt DA, Wilhelm KP, Miller DL, Maibach HI (1998) Cumulative irritation in older and younger skin: a comparison. Acta Derm Venereol 78(4):279–283CrossRefPubMed
13.
Thyssen JP, Johansen JD, Linneberg A, Menne T (2010) The epidemiology of hand eczema in the general population—prevalence and main findings. Contact Dermatitis 62(2):75–87CrossRefPubMed
14.
Jakasa I, Verberk MM, Esposito M, Bos JD, Kezic S (2007) Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol 127(1):129–134CrossRefPubMed
15.
Lerbaek A, Kyvik KO, Mortensen J, Bryld LE, Menne T, Agner T (2007) Heritability of hand eczema is not explained by comorbidity with atopic dermatitis. J Invest Dermatol 127(7):1632–1640CrossRefPubMed
16.
Gibson-Smith B, Fleming CJ, Forsyth A (1998) Contact sensitivity to tixocortol pivalate in sisters. Contact Dermatitis 38(6):351–352CrossRefPubMed
17.
Warshaw EM, Hagen SL, DeKoven JG et al (2017) Occupational contact dermatitis in North American production workers referred for patch testing: retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group 1998 to 2014. Dermatitis 28(3):183–194CrossRefPubMed
18.
King TC (2007) 2—inflammation, inflammatory mediators, and immune-mediated disease. In: Elsevier’s integrated pathology. Mosby, Philadelphia, pp 21–57CrossRef
19.
Friedmann PS (2007) The relationships between exposure dose and response in induction and elicitation of contact hypersensitivity in humans. Br J Dermatol 157(6):1093–1102CrossRefPubMed
20.
Nguyen SH, Dang TP, MacPherson C, Maibach H, Maibach HI (2008) Prevalence of patch test results from 1970 to 2002 in a multi-centre population in North America (NACDG). Contact Dermatitis 58(2):101–106CrossRefPubMed
21.
Lunder T, Kansky A (2000) Increase in contact allergy to fragrances: patch-test results 1989–1998. Contact Dermatitis 43(2):107–109CrossRefPubMed
22.
Mortz CG, Bindslev-Jensen C, Andersen KE (2013) Prevalence, incidence rates and persistence of contact allergy and allergic contact dermatitis in the Odense Adolescence Cohort Study: a 15-year follow-up. Br J Dermatol 168(2):318–325CrossRefPubMed
23.
Peiser M, Tralau T, Heidler J, Api AM, Arts JHE, Basketter DA, English J, Diepgen TL, Fuhlbrigge RC, Gaspari AA, Johansen JD, Karlberg AT, Kimber I, Lepoittevin JP, Liebsch M, Maibach HI, Martin SF, Merk HF, Platzek T, Rustemeyer T, Schnuch A, Vandebriel RJ, White IR, Luch A (2012) Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Current knowledge assembled at an international workshop at BfR, Germany. Cell Mol Life Sci 69(5):763–781CrossRefPubMed
24.
Pongpairoj K, Puangpet P, Thaiwat S, McFadden JP (2017) Diagnosing allergic contact dermatitis through elimination, Perception, Detection and Deduction. Am J Clin Dermatol
25.
Burckhardt W (1959) Contact eczema caused by hydrocortisone. Hautarzt 10:42–43PubMed
26.
Wilkinson SM, Jones MF (1996) Corticosteroid usage and binding to arginine: determinants of corticosteroid hypersensitivity. Br J Dermatol 135(2):225–230CrossRefPubMed
27.
Baeck M, Marot L, Nicolas JF, Pilette C, Tennstedt D, Goossens A (2009) Allergic hypersensitivity to topical and systemic corticosteroids: a review. Allergy 64(7):978–994CrossRefPubMed
28.
Coopman S, Degreef H, Dooms-Goossens A (1989) Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol 121(1):27–34CrossRefPubMed
29.
30.
Lepoittevin JP, Drieghe J, Dooms-Goossens A (1995) Studies in patients with corticosteroid contact allergy. Understanding cross-reactivity among different steroids. Arch Dermatol 131(1):31–37CrossRefPubMed
31.
Wilkinson SM, English JS (1991) Hydrocortisone sensitivity: a prospective study of the value of tixocortol pivalate and hydrocortisone acetate as patch test markers. Contact Dermatitis 25(2):132–133CrossRefPubMed
32.
Lauerma AI, Tarvainen K, Forstrom L, Reitamo S (1993) Contact hypersensitivity to hydrocortisone-free-alcohol in patients with allergic patch test reactions to tixocortol pivalate. Contact Dermatitis 28(1):10–14CrossRefPubMed
33.
Jacob SE, Steele T Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol 54(4):723–727
34.
Davis MD, El-Azhary RA, Farmer SA (2007) Results of patch testing to a corticosteroid series: a retrospective review of 1188 patients during 6 years at Mayo Clinic. J Am Acad Dermatol 56(6):921–927CrossRefPubMed
35.
Gonul M, Gul U (2005) Detection of contact hypersensitivity to corticosteroids in allergic contact dermatitis patients who do not respond to topical corticosteroids. Contact Dermatitis 53(2):67–70CrossRefPubMed
36.
Baeck M, Chemelle JA, Goossens A, Nicolas JF, Terreux R (2011) Corticosteroid cross-reactivity: clinical and molecular modelling tools. Allergy 66(10):1367–1374CrossRefPubMed
37.
Baeck M, Goossens A (2012) New insights about delayed allergic hypersensitivity to corticosteroids. G Ital Dermatol Venereol 147(1):65–69PubMed
38.
Baeck M, Goossens A (2012) Immediate and delayed allergic hypersensitivity to corticosteroids: practical guidelines. Contact Dermatitis 66(1):38–45CrossRefPubMed
39.
DeKoven JG, Warshaw EM, Belsito DV et al (2017) North American contact dermatitis group patch test results 2013–2014. Dermatitis 28(1):33–46CrossRefPubMed
40.
Baeck M, Chemelle J-A, Terreux R, Drieghe J, Goossens A (2009) Delayed hypersensitivity to corticosteroids in a series of 315 patients: clinical data and patch test results. Contact Dermatitis 61(3):163–175CrossRefPubMed
41.
Kot M, Bogaczewicz J, Krecisz B, Wozniacka A (2016) Contact hypersensitivity to European baseline series and corticosteroid series Haptens in a population of adult patients with contact eczema. Acta Dermatovenerol Croat 24(1):29–36PubMed
42.
Pecquet C, Pradalier A, Dry J (1992) Allergic contact dermatitis from ethanol in a transdermal estradiol patch. Contact Dermatitis 27(4):275–276CrossRefPubMed
43.
Grebe SK, Adams JD, Feek CM (1993) Systemic sensitization to ethanol by transdermal estrogen patches. Arch Dermatol 129(3):379–380CrossRefPubMed
44.
Schwartz BK, Clendenning WE (1988) Allergic contact dermatitis from hydroxypropyl cellulose in a transdermal estradiol patch. Contact Dermatitis 18(2):106–107CrossRefPubMed
45.
Tennstedt D, Lachapelle J-M (1990) Allergic contact dermatitis from colophony in a nitroglycerin transdermal therapeutic system. Contact Dermatitis 23(4):254–255CrossRef
46.
Jordan WP Jr (1997) Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Contact Dermat 8(2):108–113PubMed
47.
Ta V, Chin WK, White AA (2014) Allergic contact dermatitis to testosterone and estrogen in transdermal therapeutic systems. Dermatitis 25(5):279CrossRefPubMed
48.
Padwick ML, Endacott J, Whitehead MI (1985) Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol 152(8):1085–1091CrossRefPubMed
49.
Corazza M, Mantovani L, Montanari A, Virgili A (2002) Allergic contact dermatitis from transdermal estradiol and systemic contact dermatitis from oral estradiol. A case report. J Reprod Med 47(6):507–509PubMed
50.
El Sayed F, Bayle-Lebey P, Marguery MC, Bazex J (1996) Systemic sensitization to 17-beta estradiol induced by transcutaneous administration. Ann Dermatol Venereol 123(1):26–28PubMed
51.
Koch P (2001) Allergic contact dermatitis from estradiol and norethisterone acetate in a transdermal hormonal patch. Contact Dermatitis 44(2):112–113CrossRefPubMed
52.
McBurney EI, Noel SB, Collins JH (1989) Contact dermatitis to transdermal estradiol system. J Am Acad Dermatol 20(3):508–510CrossRefPubMed
53.
Boehncke WH, Gall H (1996) Type-IV hypersensitivity to topical estradiol in a patient tolerant to it orally. Contact Dermatitis 35(3):187–188CrossRefPubMed
54.
Warshaw EM, Belsito DV, Taylor JS, Sasseville D, DeKoven JG, Zirwas MJ, Fransway AF, Mathias CGT, Zug KA, DeLeo VA, Fowler JF Jr, Marks JG, Pratt MD, Storrs FJ, Maibach HI (2013) North American Contact Dermatitis Group patch test results: 2009 to 2010. Dermatitis 24(2):50–59CrossRefPubMed
55.
Warshaw EM, Maibach HI, Taylor JS et al (2015) North American contact dermatitis group patch test results: 2011–2012. Dermatitis 26(1):49–59CrossRefPubMed
56.
Fransway AF, Zug KA, Belsito DV, DeLeo VA, Fowler JF Jr, Maibach HI, Marks JG, Mathias CGT, Pratt MD, Rietschel RL, Sasseville D, Storrs FJ, Taylor JS, Warshaw EM, Dekoven J, Zirwas M (2013) North American Contact Dermatitis Group patch test results for 2007–2008. Dermatitis 24(1):10–21CrossRefPubMed
57.
Pratt MD, Belsito DV, DeLeo VA, Fowler JF Jr, Fransway AF, Maibach HI, Marks JG, Mathias CG, Rietschel RL, Sasseville D, Sherertz EF, Storrs FJ, Taylor JS, Zug K (2004) North American Contact Dermatitis Group patch-test results, 2001–2002 study period. Dermatitis 15(4):176–183PubMed
58.
Warshaw EM, Belsito DV, DeLeo VA, Fowler JF Jr, Maibach HI, Marks JG, Toby Mathias CG, Pratt MD, Rietschel RL, Sasseville D, Storrs FJ, Taylor JS, Zug KA (2008) North American Contact Dermatitis Group patch-test results, 2003–2004 study period. Dermatitis 19(3):129–136PubMed
59.
Zug KA, Warshaw EM, Fowler JF Jr et al (2009) Patch-test results of the North American Contact Dermatitis Group 2005–2006. Dermatitis 20(3):149–160PubMed
60.
Thyssen JP, Engkilde K, Menne T, Johansen JD (2011) Prevalence of benzocaine and lidocaine patch test sensitivity in Denmark: temporal trends and relevance. Contact Dermatitis 65(2):76–80CrossRefPubMed
61.
Sidhu SK, Shaw S, Wilkinson JD (1999) A 10-year retrospective study on benzocaine allergy in the United Kingdom. Am J Contact Dermat. 10(2):57–61CrossRefPubMed
62.
Beck MH, Holden A (1988) Benzocaine—an unsatisfactory indicator of topical local anaesthetic sensitization for the U.K. Br J Dermatol 118(1):91–94CrossRefPubMed
63.
Gilissen L, Goossens A (2016) Frequency and trends of contact allergy to and iatrogenic contact dermatitis caused by topical drugs over a 25-year period. Contact Dermatitis 75(5):290–302CrossRefPubMed
64.
Akyol A, Boyvat A, Peksari Y, Gurgey E (2005) Contact sensitivity to standard series allergens in 1038 patients with contact dermatitis in Turkey. Contact Dermatitis 52(6):333–337CrossRefPubMed
65.
Lazarov A (2006) European Standard Series patch test results from a contact dermatitis clinic in Israel during the 7-year period from 1998 to 2004. Contact Dermatitis 55(2):73–76CrossRefPubMed
66.
Cheng S, Cao M, Zhang Y, Peng S, Dong J, Zhang D, Jiang Z, He Y (2011) Time trends of contact allergy to a modified European baseline series in Beijing between 2001 and 2006. Contact Dermatitis 65(1):22–27CrossRefPubMed
67.
Yin R, Huang XY, Zhou XF, Hao F (2011) A retrospective study of patch tests in Chongqing, China from 2004 to 2009. Contact Dermatitis 65(1):28–33CrossRefPubMed
68.
Lam WS, Chan LY, Ho SC, Chong LY, So WH, Wong TW (2008) A retrospective study of 2585 patients patch tested with the European standard series in Hong Kong (1995–99). Int J Dermatol 47(2):128–133CrossRefPubMed
69.
Boonchai W, Iamtharachai P, Sunthonpalin P (2008) Prevalence of allergic contact dermatitis in Thailand. Dermatitis 19(3):142–145PubMed
70.
Brinca A, Cabral R, Goncalo M (2013) Contact allergy to local anaesthetics-value of patch testing with a caine mix in the baseline series. Contact Dermatitis 68(3):156–162CrossRefPubMed
71.
Warshaw EM, Schram SE, Belsito DV, DeLeo V, Fowler JF Jr, Maibach HI, Marks JG Jr, Mathias CG, Pratt MD, Rietschel RL, Sasseville D, Storrs FJ, Taylor JS, Zug KA (2008) Patch-test reactions to topical anesthetics: retrospective analysis of cross-sectional data, 2001 to 2004. Dermatitis 19(2):81–85PubMed
72.
Erdmann SM, Sachs B, Merk HF (2001) Systemic contact dermatitis from cinchocaine. Contact Dermatitis 44(4):260–261CrossRefPubMed
73.
Marques C, Faria E, Machado A, Goncalo M, Goncalo S (1995) Allergic contact dermatitis and systemic contact dermatitis from cinchocaine. Contact Dermatitis 33(6):443CrossRefPubMed
74.
Yamadori Y, Oiso N, Hirao A, Kawara S, Kawada A (2009) Allergic contact dermatitis from dibucaine hydrochloride, chlorpheniramine maleate, and naphazoline hydrochloride in an over-the-counter topical antiseptic. Contact Dermatitis 61(1):52–53CrossRefPubMed
75.
LaBerge L, Pratt M, Fong B, Gavigan G (2011) A 10-year review of p-phenylenediamine allergy and related para-amino compounds at the Ottawa Patch Test Clinic. Dermatitis 22(6):332–334PubMed
76.
Vogel TA, Coenraads PJ, Bijkersma LM, Vermeulen KM, Schuttelaar ML, Group EFS (2015) p-Phenylenediamine exposure in real life—a case-control study on sensitization rate, mode and elicitation reactions in the northern Netherlands. Contact Dermatitis 72(6):355–361CrossRefPubMed
77.
Speca SJ, Boynes SG, Cuddy MA (2010) Allergic reactions to local anesthetic formulations. Dent Clin N Am 54(4):655–664CrossRefPubMed
78.
Gall H, Kaufmann R, Kalveram CM (1996) Adverse reactions to local anesthetics: analysis of 197 cases. J Allergy Clin Immunol 97(4):933–937CrossRefPubMed
79.
Jenerowicz D, Polanska A, Glinska O, Czarnecka-Operacz M, Schwartz RA (2014) Allergy to lidocaine injections: comparison of patient history with skin testing in five patients. Postepy Dermatol Alergol 31(3):134–138CrossRefPubMedPubMedCentral
80.
Gonzalez-Delgado P, Anton R, Soriano V, Zapater P, Niveiro E (2006) Cross-reactivity among amide-type local anesthetics in a case of allergy to mepivacaine. J Investig Allergol Clin Immunol 16(5):311–313PubMed
81.
Fuzier R, Lapeyre-Mestre M, Mertes PM et al (2009) Immediate- and delayed-type allergic reactions to amide local anesthetics: clinical features and skin testing. Pharmacoepidemiol Drug Saf 18(7):595–601CrossRefPubMed
82.
Ing Lorenzini K, Gay-Crosier Chabry F, Piguet C, Desmeules J (2016) Meta-xylene: identification of a new antigenic entity in hypersensitivity reactions to local anesthetics. J Allergy Clin Immunol Pract 4(1):162–164CrossRefPubMed
83.
Corbo MD, Weber E, DeKoven J (2016) Lidocaine allergy: do positive patch results restrict future use? Dermatitis 27(2):68–71CrossRefPubMed
84.
Purcell SM, Dixon SL (1985) Allergic contact dermatitis to dyclonine hydrochloride simulating extensive herpes simplex labialis. J Am Acad Dermatol 12(2 Pt 1):231–234CrossRefPubMed
85.
Maibach HI (1986) Dyclonine hydrochloride, local anaesthetic allergic contact dermatitis. Contact Dermatitis 14(2):114CrossRefPubMed
86.
Hylwa SA, Warshaw E (2014) Contact allergy to pramoxine (pramocaine): the importance of testing to personal products. Dermatitis 25(3):147–148CrossRefPubMed
87.
88.
García F (2007) Contact dermatitis from prilocaine with cross-sensitivity to pramocaine and bupivacaine. Contact Dermatitis 56(2):120–121CrossRefPubMed
89.
90.
91.
van Ketel WG (1983) Contact allergy to different antihaemorrhoidal anaesthetics. Contact Dermatitis 9(6):512–513CrossRefPubMed
92.
93.
Goossens A, Linsen G (1998) Contact allergy to antihistamines is not common. Contact Dermatitis 39(1):38–39CrossRefPubMed
94.
Lew BL, Haw CR, Lee MH (2004) Cutaneous drug eruption from cetirizine and hydroxyzine. J Am Acad Dermatol 50(6):953–956CrossRefPubMed
95.
Zuidema J (1985) Ethylenediamine, profile of a sensitizing excipient. Pharm Weekbl Sci 7(4):134–140CrossRefPubMed
96.
Yoshizawa A, Araki Y, Kobayashi N, Kudo K (1999) A case of aminophylline hypersensitivity reaction due to ethylenediamine. Arerugi 48(11):1206–1211PubMed
97.
Terzian CG, Simon PA (1992) Aminophylline hypersensitivity apparently due to ethylenediamine. Ann Emerg Med 21(3):312–314CrossRefPubMed
98.
de la Hoz B, Perez C, Tejedor MA, Lazaro M, Salazar F, Cuevas M (1993) Immediate adverse reaction to aminophylline. Ann Allergy 71(5):452–454PubMed
99.
Fisher AA (1976) Highlights of the first international symposium on contact dermatitis. Cutis 18(5):645–662PubMed
100.
Van Hecke E (1975) Ethylenediamine sensitivity from exposure to epoxy resin hardeners and Mycolog cream. Contact Dermatitis 1(6):344–348CrossRefPubMed
101.
Shakouri AA, Bahna SL (2013) Hypersensitivity to antihistamines. Allergy and Asthma Proceedings 34(6):488–496CrossRefPubMed
102.
Tella R, Gaig P, Bartra J, Garcia-Ortega P (2002) Urticaria to cetirizine. J Investig Allergol Clin Immunol 12(2):136–137PubMed
103.
Kranke B, Mayr-Kanhauser S (2005) Urticarial reaction to the antihistamine levocetirizine dihydrochloride. Dermatology 210(3):246–247CrossRefPubMed
104.
Sanchez Morillas L, Rojas Perez-Ezquerra P, Reano Martos M, Sanz ML, Laguna Martinez JJ (2011) Urticaria due to antihistamines. J Investig Allergol Clin Immunol 21(1):66–68PubMed
105.
Bonnel RA, La Grenade L, Karwoski CB, Beitz JG (2003) Allergic contact dermatitis from topical doxepin: Food and Drug Administration’s postmarketing surveillance experience. J Am Acad Dermatol 48(2):294–296CrossRefPubMed
106.
Taylor JS, Praditsuwan P, Handel D, Kuffner G (1996) Allergic contact dermatitis from doxepin cream. One-year patch test clinic experience. Arch Dermatol 132(5):515–518CrossRefPubMed
107.
Nethercott JR, Holness DL, Adams RM, Belsito DV, de Leo VA, Emmett EA, Fowler J, Fisher AA, Larsen W, Maibach H, Marks J, Mitchell J, Rietschel R, Rosenthal L, Schorr W, Storrs F, Taylor J (1991) Patch testing with a routine screening tray in North America, 1985 through 1989: II. Gender and response. Dermatitis 2(2):130–134CrossRef
108.
Marks JG Jr, Belsito DV, DeLeo VA et al (2000) North American Contact Dermatitis Group patch-test results, 1996–1998. Arch Dermatol 136(2):272–273CrossRefPubMed
109.
Marks JGJ, Belsito DV, DeLeo VA et al (2003) North American Contact Dermatitis Group patch-test results, 1998 to 2000. Dermatitis 14(2):59–62
110.
Forstrom L, Pirila V, Pirila L (1979) Cross-sensitivity within the neomycin group of antibiotics. Acta Derm Venereol Suppl (Stockh) 59(85):67–69
111.
Schorr WF, Wenzel FJ, Hededus SI (1973) Cross-sensitivity and aminoglycoside antibiotics. Arch Dermatol 107(4):533–539CrossRefPubMed
112.
Kimura M, Kawada A (1998) Contact sensitivity induced by neomycin with cross-sensitivity to other aminoglycoside antibiotics. Contact Dermatitis 39(3):148–150CrossRefPubMed
113.
Shi K, Caldwell SJ, Fong DH, Berghuis AM (2013) Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance. Front Cell Infect Microbiol 3:22CrossRefPubMedPubMedCentral
114.
Goh CL (1986) Anaphylaxis from topical neomycin and bacitracin. Australas J Dermatol 27(3):125–126CrossRefPubMed
115.
Bommarito L, Mietta S, Cadario G (2015) Anaphylaxis after application of topical bacitracin-neomycin powder. Ann Allergy Asthma Immunol 115(1):74–75CrossRefPubMed
116.
Lin FL, Woodmansee D, Patterson R Near-fatal anaphylaxis to topical bacitracin ointment. J Allergy Clin Immunol 101(1):136–137
117.
Freiler JF, Steel KE, Hagan LL, Rathkopf MM, Roman-Gonzalez J (2005) Intraoperative anaphylaxis to bacitracin during pacemaker change and laser lead extraction. Ann Allergy Asthma Immunol 95(4):389–393CrossRefPubMed
118.
Saryan JA, Dammin TC, Bouras AE Anaphylaxis to topical bacitracin zinc ointment. Am J Emerg Med 16(5):512–513
119.
Damm S (2011) Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health Syst Pharm 68(4):323–327CrossRefPubMed
120.
Blas M, Briesacher KS, Lobato EB (2000) Bacitracin irrigation: a cause of anaphylaxis in the operating room. Anesth Analg 91(4):1027–1028 table of contentsCrossRefPubMed
121.
Parenti MA, Hatfield SM, Leyden JJ (1987) Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm 6(10):761–770PubMed
122.
123.
Eedy DJ (1995) Mupirocin allergy in the setting of venous ulceration. Contact Dermatitis 32(4):240–241CrossRefPubMed
124.
Zappi EG, Brancaccio RR (1997) Allergic contact dermatitis from mupirocin ointment. J Am Acad Dermatol 36(2 Pt 1):266CrossRefPubMed
125.
Gette MT, Marks JG Jr, Maloney ME (1992) Frequency of postoperative allergic contact dermatitis to topical antibiotics. Arch Dermatol 128(3):365–367CrossRefPubMed
126.
Bork K, Brauers J, Kresken M (1989) Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections—an open multicentre trial. Br J Clin Pract 43(8):284–288PubMed
127.
Warshaw EM, Wang MZ, Maibach HI, Belsito DV, Zug KA, Taylor JS, Mathias CGT, Sasseville D, Zirwas MJ, Fowler JF Jr, DeKoven JG, Fransway AF, DeLeo VA, Marks JG Jr, Pratt MD, Storrs FJ (2013) Patch test reactions associated with sunscreen products and the importance of testing to an expanded series: retrospective analysis of North American Contact Dermatitis Group data, 2001 to 2010. Dermatitis 24(4):176–182CrossRefPubMed
128.
Beleznay K, de Gannes G, Kalia S (2014) Analysis of the prevalence of allergic contact dermatitis to sunscreen: a cohort study. J Cutan Med Surg 18(1):15–19CrossRefPubMed
129.
Scheuer E, Warshaw E (2006) Sunscreen allergy: a review of epidemiology, clinical characteristics, and responsible allergens. Dermatitis 17(1):3–11CrossRefPubMed
130.
de Groot AC, Veenstra M (2010) Formaldehyde-releasers in cosmetics in the USA and in Europe. Contact Dermatitis 62(4):221–224CrossRefPubMed
131.
132.
133.
Breithaupt A, Jacob SE (2008) Thimerosal and the relevance of patch-test reactions in children. Dermatitis 19(5):275–277PubMed
134.
Freiman A, Al-Layali A, Sasseville D (2003) Patch testing with thimerosal in a Canadian center: an 11-year experience. Am J Contact Dermat 14(3):138–143PubMed
135.
136.
Rodrigues DF, Neves DR, Pinto JM, Alves MF, Fulgencio AC (2012) Results of patch-tests from Santa Casa de Belo Horizonte Dermatology Clinic, Belo Horizonte, Brazil, from 2003 to 2010. An Bras Dermatol 87(5):800–803CrossRefPubMed
137.
Scheman A, Rakowski EM, Chou V, Chhatriwala A, Ross J, Jacob SE (2013) Balsam of Peru: past and future. Dermatitis 24(4):153–160CrossRefPubMed
138.
Larsen W, Nakayama H, Fischer T, Elsner P, Frosch P, Burrows D, Jordan W, Shaw S, Wilkinson J, Marks J Jr, Sugawara M, Nethercott M, Nethercottdagger J (1998) A study of new fragrance mixtures. Am J Contact Dermat 9(4):202–206PubMed
139.
Frosch PJ, Pirker C, Rastogi SC, Andersen KE, Bruze M, Svedman C, Goossens A, White IR, Uter W, Arnau EG, Lepoittevin JP, Menne T, Johansen JD (2005) Patch testing with a new fragrance mix detects additional patients sensitive to perfumes and missed by the current fragrance mix. Contact Dermatitis 52(4):207–215CrossRefPubMed
140.
Bruze M, Andersen KE, Goossens A (2008) Escd, Eecdrg. Recommendation to include fragrance mix 2 and hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyral) in the European baseline patch test series. Contact Dermatitis 58(3):129–133CrossRefPubMed
141.
Johansen JD (2003) Fragrance contact allergy: a clinical review. Am J Clin Dermatol 4(11):789–798CrossRefPubMed
142.
Nardelli A, Carbonez A, Drieghe J, Goossens A (2013) Results of patch testing with fragrance mix 1, fragrance mix 2, and their ingredients, and Myroxylon pereirae and colophonium, over a 21-year period. Contact Dermatitis 68(5):307–313CrossRefPubMed
143.
Engfeldt M, Hagvall L, Isaksson M et al (2017) Patch testing with hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC)—a multicentre study of the Swedish Contact Dermatitis Research Group. Contact Dermatitis 76(1):34–39CrossRefPubMed
Metadata
Title
Contact Dermatitis to Medications and Skin Products
Authors
Henry L. Nguyen
James A. Yiannias
Publication date
01-02-2019
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2019
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-018-8705-0

Other articles of this Issue 1/2019

Clinical Reviews in Allergy & Immunology 1/2019 Go to the issue

ReviewPaper

Contact Dermatitis in Atopic Dermatitis Children—Past, Present, and Future

ReviewPaper

Food-Related Contact Dermatitis, Contact Urticaria, and Atopy Patch Test with Food

ReviewPaper

Contact Dermatitis to Cosmetics

ReviewPaper

Irritant Contact Dermatitis

ReviewPaper

The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment

ReviewPaper

Occupational and Hand Dermatitis: a Practical Approach
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits